ShuimuBio is a rapidly evolving AI & CryoEM Powered Drug Discovery Platform. Leverage AI & CryoEM to accelerate and push the boundaries of modern-day drug discovery.
"Scientific breakthroughs often build upon the successful visualization of objects invisible to the human eye." CryoEM technology is transforming the drug discovery landscape by enabling scientists to "look" at near-native atomic-resolution protein structures that are key to drug design. We are pushing the boundaries even further by taking advantage of the state-of-the-art AI & CryoEM technology.
See unseeable. Drug undruggable.
Most of the validated biological molecule targets of next-generation drugs such as transmembrane receptors and dynamic complexes are proteins notoriously difficult to crystallize, raising a high bar for scientists to obtain their structures through the traditional crystallography method. Our advanced 300kV cryoEM platform opens the door to many of these targets, acquiring their structures at near-atomic resolution, and thus turning them into seeable and druggable targets.
Boost structure accuracy and resolution via top-notch AI.
A high-accuracy molecule structure model of the biological target at atomic resolution is critical to a successful structure-based drug discovery effort. While an experienced structure biologist is capable of constructing reasonably reliable structures, structure determination is a complex task and humans have limitations. We are incorporating deep learning to rapidly improve model accuracy and map resolution.
Speed up everything with ShuimuBio Powered CryoEM Computing Platform.
As cryoEM quickly becomes the most preferred technology for structural characterization and candidate screening, the throughput is required to facilitate faster drug discovery. We are dedicated to providing the most powerful cryoEM computing platform in the world, making high-throughput cryoEM a new norm. During the Omicron outbreak, dozens of Omicron antigen-antibody complex structures have been successfully resolved by us (highest resolution at 2.5Å) within a few days.
Be the first, not the better.
We are ready to team up with aspiring partners who are determined to bring first-in-class drugs and pioneer neo therapies to the world. Combining AI and CryoEM technology, previously impossible ideas are now possible. “It is very easy to answer many fundamental biological questions: you just look at the thing.” Let's unveil the mysteries and make the most impactful breakthroughs.
Case Study: CryoEM-enabled conformational epitope mapping inspires novel and highly differentiated antibody development
Serial Entrepreneur Allen Guo: Beyond Boundaries
Next Tech opens, Shuimu Biosciences helps French pharmaceutical companies to innovate in China
Shuimu Biosciences, Biocytogen and others collaborate to publish new research paper on COVID19-neutralizing antibody in Cell Discovery
CONTACT
SHUIMUBIO
Hi@shuimubio.com
+ 86 18510728199
B1,National Institute of Biological Sciences，
Changping Beijing, PR China
